TORONTO–(BUSINESS WIRE)–Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announces that the Company has completed a consolidation of its outstanding common shares (the “Common Shares”) on the basis of one post-consolidation Common Share for every 12 pre-consolidation Common Shares (the “Consolidation”). The Company believes that the Consolida.
This excerpt is quoted from the original release. Read the full announcement on Business Wire.
Brief Summary
In a significant move, Satellos Bioscience Inc. has announced a consolidation of its outstanding shares to pave the way for a proposed listing on Nasdaq. This strategic step involves consolidating shares on a ratio of 1:12, simplifying capital structure and enhancing liquidity.
- Share Ratio: 1 post-consolidation share for every 12 pre-consolidation shares.
- Market Moves: Aims to improve visibility for investors.
- Company Overview: Satellos specializes in medicines for degenerative muscle diseases.
Why it matters: This consolidation may enhance investor confidence and pave the way for an expanded market presence.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by Business Wire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.